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Abstract
The chemotherapeutic use of cisplatin is limited by its severe side effects. In this study,
by conducting different omics data analyses, we demonstrated that cisplatin induces cell
death in a proximal tubular cell line by suppressing glycolysis- and tricarboxylic acid (TCA)/
mitochondria-related genes. Furthermore, analysis of the urine from cisplatin-treated rats
revealed the lower expression levels of enzymes involved in glycolysis, TCA cycle, and
genes related to mitochondrial stability and confirmed the cisplatin-related metabolic abnor-
malities. Additionally, an increase in the level of p53, which directly inhibits glycolysis, has
been observed. Inhibition of p53 restored glycolysis and significantly reduced the rate of
cell death at 24 h and 48 h due to p53 inhibition. The foremost reason of cisplatin-related
cytotoxicity has been correlated to the generation of mitochondrial reactive oxygen species
(ROS) that influence multiple pathways. Abnormalities in these pathways resulted in the
collapse of mitochondrial energy production, which in turn sensitized the cells to death.
The quenching of ROS led to the amelioration of the affected pathways. Considering these
observations, it can be concluded that there is a significant correlation between cisplatin
and metabolic dysfunctions involving mROS as the major player.
Introduction
Platinum-derived chemotherapeutic agents, including the parent compound cis-diamminedi-
chloroplatinum (II) (cisplatin), are the principal therapeutic agents to treat various cancers,
including ovarian, testicular, and bladder cancer [1,2]. However, the therapeutic use of cisplatin
is limited by its irreversible side effects, including transcription inhibition, cell cycle arrest, gen-
eration of reactive oxygen species (ROS), and apoptosis [3].
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In recent years, several studies demonstrated that cisplatin-induced cytotoxicity is closely
related to increased ROS generation [4,5] ROS is a by-product of the normal cellular metabo-
lism; however, excessive amounts can cause detrimental effects. In particular, ROS is an
important factor in the apoptosis pathway; increased ROS generation alters the mitochondrial
membrane potential (MMP) and damages the respiratory chain, which ultimately triggers the
apoptotic process [6,7]. Previous reports demonstrated that compounds that interfere with
ROS generation could inhibit cisplatin-induced apoptosis; correlating cisplatin toxicity to the
activation of oxidative stress pathways [2].
P53 is an important anticancer gene that is frequently mutated in cancers. It has been
reported that cisplatin induces the expression of p53, which plays diverse roles, particularly in
regulating glycolysis genes [8–11]. Down-regulation of glycolysis genes when p53 is over-
expressed leads to apoptosis. Moreover, energy status of cell is the main determining factor in
cell survival or cell death. Severe reduction of adenosine triphosphate (ATP) level initiates
necrosis because apoptosis-dependent pathways require ATP [12]. Therefore, in cisplatin-
induced cytotoxicity, energy depletion of cells is a crucial factor that is being perpetuated by
disrupting metabolic pathways.
Cisplatin rapidly accumulates in mitochondria and deteriorates the mitochondrial structure
and metabolic function [13]. This leads to significant changes in the metabolites level related to
the tricarboxylic acid cycle (TCA cycle) and glycolysis pathway [14,15]. However, the precise
mechanism of cisplatin-induced metabolic toxicity remains elusive.
The following study aimed to elucidate the metabolic dysfunctions in a proximal tubular
cell line (human kidney 2; HK-2) following treatment with cisplatin. A systems biology
approach was employed to investigate the role of mitochondrial dysfunction and abnormal
metabolic pathways in cisplatin-induced kidney injury. Different techniques have been used to
delineate physiological and morphological anomalies. Finally, cytotoxic events induced by
cisplatin were evaluated in HK-2 cells with and without various inhibitors. Moreover, we




The cell line HK-2 (ATCC # CRL-2190; Manassas, VA, USA) was purchased from the Ameri-
can Type Culture Collection. This cell line has been widely accepted as the standard cell line
for normal renal tubular epithelium [16,17]. Cells were grown in keratinocyte-serum-free
medium supplemented with L-glutamine, epidermal growth factor, and bovine pituitary extract
(Gibco, Carlsbad, CA, USA) and maintained at 37°C under 5% CO2.
Cell proliferation assay (MTS assay)
Cell proliferation was measured colorimetrically using 3-(4, 5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) solution (Cell Titer 96H; Pro-
mega, Madison, WI, USA). HK-2 cells were grown in 96-well plates at a density of 10,000 cells
per well. After treatment for the indicated times, MTS solution (10 μL/well) was added to the
wells, the cells were incubated for 3 h at 37°C, and absorbance was measured using the VERSA
microplate reader (Turner Biosystems, Sunnyvale, CA, USA).
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Lactate dehydrogenase assay
HK-2 cells were seeded in a 96-well plate and grown at 37°C and 5% CO2 overnight. Cell viabil-
ity was determined at different times using the CytoTox-Glo cytotoxicity assay (Promega).
Briefly, 50 μL of CytoTox-Glo cytotoxicity assay reagent was added to each well and the plate
was incubated at room temperature for 15 min. The luminescence intensity was measured
using the VERITAS microplate luminometer (Turner Biosystems).
Lactate measurement in glycolysis and NAC treatment
Lactate concentration was measured using the Lactate Colorimetric Assay Kit (Abcam,
Cambridge, MA, USA). Equal number of cells were suspend in Lactate Assay Buffer and all
experimental procedure was performed according to the instruction of the manufacturer. Experi-
ment was repeated three times and absorbance was measured using the VERSAmicroplate
reader (Turner Biosystems). For p53 inhibition, 20 μMpifithrin-α (PFT-α) (Sigma-Aldrich, MO,
USA) was treated for 1 h before the cisplatin treatment and quantifications were made at indi-
cated time points. For N-acetylcysteine (NAC) (Sigma-Aldrich), which is a powerful antioxidant,
10 μMNAC was pretreated for 1 h and then cisplatin was applied. All experiments related to
PFT-α and NAC followed the same treatment process.
ATP quantification assay
ATP concentration was quantitatively determined using an ATP determination kit (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions. Cells were resuspended in
1× reaction buffer. Then, 10 μL of the cell suspension was transferred to a new 96-well plate
and 90 μL of standard reaction solution was added. The plate was incubated for 15 min at
room temperature. ATP was quantified using the VERITAS microplate luminometer (Turner
Biosystems) and the LAS-1000 system (FUJIFILM, Tokyo, Japan).
Glucose assay
The intracellular glucose concentration was measured using the Amplex Red glucose/glucose
oxidase assay kit (Invitrogen) according to the instructions of the manufacturer. Cells were
lysed using 1× reaction buffer. Then, 100 μL of the lysate was resuspended in 400 μL of 1×
reaction buffer. Next, 50 μL of the glucose working solution was added to 50 μL of cell lysate
in a 96-well plate. The mixture was incubated in the dark for 30 min at room temperature.
Then, the fluorescence was measured using the VERITAS microplate luminometer (Turner
Biosystems).
Annexin V apoptosis assay
Apoptosis was measured using the FITC Annexin V apoptosis detection kit II (BD Biosciences,
San Diego, CA, USA). Briefly, cells were resuspended in 1× binding buffer. Then, 50 μL of the
solution was transferred to a 1.5-mL tube and 10 μL of Annexin V and 10 μL of PI staining
solution were added. Subsequently, the cells were mixed by swirling and incubated for 15 min
at room temperature in the dark. Finally, the cells were diluted in 200 μL of phosphate-buffered
saline (PBS) for analysis by flow cytometry (FACSAria III, BD Biosciences). Data were pro-
cessed using the FACSDiva software (BD Biosciences).
ROS generation detection assay
ROS was measured using the 2',7'-dichlorfluorescein-diacetate (DCFH-DA) fluorescence dye
(Molecular Probe, Eugene, OR, USA). Briefly, 1 mL of the cell suspension was transferred to a
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1.5-mL culture tube and 1 μL of DCFH-DA staining solution was added. Subsequently, cells
were gently mixed and incubated for 15 min at 37°C in the dark. Next, cells were washed again
and resuspended in 300 μL of cold PBS. Finally, ROS generation was monitored using a flow
cytometer (FACSAria III, BD Biosciences), and data were processed with the FACSDiva soft-
ware (BD Biosciences).
Mitochondrial membrane potential (JC-1) assay
MMP was assessed by staining the cells with the JC-1 fluorescence dye (Molecular Probe).
Briefly, 1 mL of the cell suspension was transferred to a 1.5-mL culture tube and 0.5 μL of JC-1
staining solution was added to cells. Next, the cells were gently mixed and incubated for 5 min
in an incubator (37°C) in the dark. Cells were washed again and resuspended in 300 μL of cold
PBS. MMP was analyzed using flow cytometry (FACSAria III, BD Biosciences), and data were
processed with the FACSDiva software (BD Biosciences).
Two-photon (TP) fluorescence microscopy
TP fluorescence microscopy images of SHP-Mito-labeled cells were obtained with spectral con-
focal and multiphoton microscopes (Leica TCS SP8MP) with ×40 oil and ×63 oil objectives,
numerical apertures (1.30 and 1.40, respectively). TP fluorescence microscopy images were
obtained with a DMI6000B Microscope (Leica) by exciting the probe with a mode-locked tita-
nium-sapphire laser source (Mai Tai HP; Spectra Physics, 80 MHz pulse frequency, 100 fs
pulse width) set at a wavelength of 750 nm. To obtain images in the 400–470 nm (blue) and
530–600 (yellow) ranges, internal photomultiplier tubes were used to collect the signals in 8-bit
unsigned 1024 × 1024 pixels at a scan speed of 400 Hz. Ratiometric image processing carried
out using MetaMorph software.
Western blot analysis
After treatment, proteins were isolated by resuspending the cells in M-PER mammalian pro-
tein extraction reagent (Thermo Scientific, Waltham, MA, USA) supplemented with the Halt
protease inhibitor cocktail (Thermo Scientific). Extracts were loaded onto 10% polyacrylamide
gels and transferred to Hybond enhanced chemiluminescence (ECL) membranes (GE Health-
care Life Sciences, Little Chalfont, Buckinghamshire, UK). Membranes were blocked with 5%
skim milk. The membranes were then incubated with specific primary antibodies, i.e., p-p53
(ser15) (1:1000) and β-actin (1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and p53 (Millipore, MA, USA), which were diluted with PBS containing 0.05% Tween 20
(PBST), at 4°C with gentle shaking overnight. After several cycles of washing, the membranes
were incubated for 2 h with ImmunoPure goat anti-mouse or anti-rabbit IgG peroxidase-con-
jugated antibody (Thermo Scientific) diluted in PBST (1:1,000). After washing several times
with PBST, proteins were detected using the Pierce ECL western blotting substrate (Thermo
Scientific). The blots were exposed to autoradiography films, which were analyzed with the
LAS-1000 system (FUJIFILM).
RNA isolation and qRT-PCR
The RNeasy mini kit (QIAGEN, Valencia, CA, USA) was used to isolate total RNA. Then, 500 ng
of total RNA was reverse transcribed to cDNAwith a reverse transcription kit (QIAGEN). PCR
was performed using the Maxima SYBR Green/ROX qPCRmaster mix (Thermo Scientific).
Thermal cycling was performed with an initial denaturation phase of 10 min at 95°C, followed by
40 cycles of 30 s at 95°C, 30 s at 57°C, and 1 min at 72°C. Amplifications were carried out in the
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Rotor-Gene Q (QIAGEN). Melting curve analysis was performed to confirm the specificity of the
results and reagents. For relative quantification, we used the ΔΔCTmethod with the Rotor-Gene
Q Series Software version 2.2.3. The primers used in this study are ACMSD: F: 50-GGT GCG
AGAGAA TTG CTG G-30, R: 50-TGC TGG CAA GGT CGT TGT TT-30; BIK: F: 50-GAC CTG
GAC CCT ATG GAGGAC-30, R: 5- CCT CAG TCT GGT CGT AGA TGA-30; ENDOG: F: 50-
AGC AGG TGGGCA AAT TGA G-30, R: 50-CCA GGA TGT TTG GCA CAA AGAG-30;
HIF1α: F: 50-CAC CAC AGG ACA GTA CAG GAT-30, R: 50-CGT GCT GAA TAA TAC CAC
TCA CA-30;HK2: F: 50-GAG CCA CCA CTC ACC CTA CT-30, R: 50-CCA GGC ATT CGG
CAA TGT G-30;OPA1: F: 50-TGT GAG GTC TGC CAG TCT TTA-30, R: 50-TGT CCT TAA
TTG GGG TCG TTG-30; PDK1: F: 50-CTG TGA TACGGA TCA GAA ACCG-30, R: 50-TCC
ACC AAA CAA TAA AGAGTG CT-30; PRKAG2: F: 50-TGC CCG TTA TTG ACC CTA TCA-
30, R: 50-CAGGCT TTGGCA TAT CAG ACA T-30; RRM2B: F: 50-AGAGGC TCG CTG TTT
CTA TGG-30, R: 50-GCA AGG CCC AAT CTG CTT TTT-30; β-actin: F: 50-ATA GCA CAG
CCT GGA TAG CAA CGT AC-30, R: 50-CAC CTT CTA CAA TGA GCT GCG TGT G-30.
Microarray analysis
Total RNA was extracted using an RNeasy mini kit (QIAGEN), and the concentration in the
samples was measured using a Micro UV-Vis fluorescence spectrophotometer (Malcom).
Probe labeling and hybridization to Affymetrix GeneAtlas Human Genome U219 chips con-
taining 49,386 probe sets were then carried out. Microarray data were normalized using the
robust multi-array average analysis via the Affymetrix Expression Console software (ver. 1.1)
(http://www.affymetrix.com/support). When examining the cisplatin-induced differences in
the expression profiles, only genes with an average log2-(treated/control) (in absolute values)
1 (which corresponded to a 2-fold change in the expression) at p< 0.01 were considered differ-
entially expressed. Moreover, the data have been submitted to Gene Expression Omnibus
(GEO) database and the GEO accession number is GSE69644.
Data processing and statistical analysis for proteome profiling
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) raw data were searched
using the SEQUEST algorithm against the ipi.HUMAN.v3.86 database with decoy sequences
using the following parameters: 2.0 Da precursor mass tolerance; 1.0 Da product ion mass tol-
erance; fully tryptic digestion; up to two missed cleavages; variable modifications: oxidation of
methionine (+15.99), carbamidomethylation of cysteine (+57.02), and acetylation of the N-ter-
minus (+43.02). PeptideProphet probability was computed using TPP v.4.5 [18] to evaluate the
SEQUEST search results. Peptides with a prophet error rate of<0.01 were regarded as identi-
fied peptides and quantified using a spectral count-based method previously suggested [19]. In
this method, the number of identified spectra assigned to each peptide from each LC-MS/MS
run (nine replicates for 0 h and 6 h and seven replicates for 24 h) was counted as peptide-level
spectral counts. Then, the peptide-level spectral counts computed from each replicate were
summed and divided by the number of replicates to calculate peptide-level average spectral
counts. With the peptide-level average spectral counts measured from 0 h, 6 h, and 24 h sam-
ples, the RSCs, the log2 ratio of abundance between two samples [20], were calculated for two
comparisons, i.e., 6 h/0 h and 24 h/0 h. To evaluate the statistical significance of the RSC value
for each peptide, empirical distributions of the RSC values were generated by 1000 random per-
mutation experiments. Peptides whose absolute RSC values are above the 99
th percentile value
of the RSCs in the empirical distributions (1.64 for 6 h and 1.82 for 24 h) were regarded as dif-
ferentially expressed peptides. Proteins that have at least one differentially expressed peptide
(DEP) were considered as differentially expressed proteins.
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LC-MS data processing and statistical analysis
Data were normalized by dividing each signal by the sum of the signals for all metabolites in
the same run. The Student’s t-test was performed for the metabolite profiles from rat urine and
serum. Metabolites with a p-value< 0.05 were regarded as differentially expressed metabolites.
In case of metabolite profiling from HK-2 cells and media, metabolites whose fold increase was
>95% compared to that of the change in the empirical distribution were selected as differen-
tially expressed metabolites.
Functional enrichment analysis
Analysis of the 5,692 DEGs and 487 DEPs was performed using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) software. The results were analyzed with the
enrichment map plug-in for Cytoscape, with which functional enrichment can be visualized
and compared [21–23].
Animals and husbandry
Male Sprague-Dawley rats (weighing approximately 180 g, 6 weeks old) were used. They were
kept in a controlled environment (at 22°C ± 2°C with 50–60% relative humidity) during a 12-h
light-dark cycle. Rats were allowed to acclimate for 1 week before the experiments and ran-
domly allocated into control and drug treatment groups with six rats per group. Animal experi-
ments were conducted in accordance with the Guide for Animal Experiments published by
the Korea Academy of Medical Sciences. The protocol was approved by the Pusan National
University–Institutional Animal Care and Use Committee (PNU-IACUC) (Permit Number
PNU-2011-00211). All efforts were made to reduce their suffering.
In vivo experimental design
Rats were administered intraperitoneally (i.p.) a single dose of cisplatin (10 mg/kg, dissolved in
0.9% saline) on day 0. It has been previously shown that this dose results in proximal tubule
cell necrosis or apoptosis, and severe damage in kidney function within 3 days after the cis-
platin injection. The vehicle control group was injected with 0.9% saline in the same manner.
Urine samples of cisplatin-treated animals were collected at 0, 1, and 3 days. Each animal was
kept in a rat metabolic cage overnight and 24-h urine samples were collected in the morning.
Animals were monitored daily by the disease activity index that includes loss of body weight,
serum levels of blood urea nitrogen (BUN) and creatinine, and hair loss as described previously
[24–26]. Animals were euthanized under anesthesia by cervical dislocation when they lost
more than 20% of starting bodyweight.
¹H-NMR spectroscopy and data processing
Analysis of the urine samples was carried out on a Varian system (Varian Medical Systems, Palo
Alto, CA, USA) with a working frequency of 600.167 MHz at a temperature of 299.1 K. Deute-
rium oxide and 3-(trimethylsilyl propionic-2,2,3,3-d4 acid) were used as field-lock frequency and
internal chemical shift reference, respectively. A single-pulse spectrum was obtained using a
Carr-Purcell-Meiboom-Gill pulse sequence to suppress the water signal. For each ¹H-NMR spec-
trum, 128 scans were collected into 32K data points, which resulted in an acquisition time of 12
min. All data were automatically apodized with an exponential function using a line broadening
of 0.2 Hz prior to Fourier transformation and calibrated to 3-(trimethylsilyl propionic-2,2,3,3-d4
acid) at δ = 0.00 ppm. Spectral assignment was performed using the Chenomx NMR Suite 7.1
software (Chenomx, Edmonton, AB, Canada) and compared to data published in the literature.
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After processing, data were reduced into 920 spectral integral regions equating to the chemical
shift range of δ (0.2–10 ppm) using the Chenomx NMR Suite.
NMRmultivariate data analysis
All binned NMR data were analyzed by principal component analysis (PCA) using the SIM-
CA-P+ 12.0 software (Umetrics, Tvistevägen, Umeå, Sweden). PCA is one of the pattern recog-
nition methods and useful to detect differences in each spectrum. To clarify the differences
among samples, orthogonal-projection to latent structure-discriminant analysis was applied.
Statistical analysis for metabolite profiling
Data were normalized by dividing each signal by the sum of the signals measured from the
same run. Metabolites with a Student’s t-test p-value< 0.05 were regarded as differentially
expressed metabolites.
Results
Cisplatin induced dose-dependent toxicity in HK-2 cells
To evaluate its toxicity, HK-2 cells were treated with varying concentrations of cisplatin (6.25,
12.5, 25, 50, or 100 μM) for 6, 12, and 24 h. We found that cell proliferation was decreased in a
dose- and time-dependent manner. Cell viability decreased to 52.5% ± 2% in the group treated
with 50 μM for 24 h (Fig 1A) implying a half-maximal inhibitory concentration as of 50 μM.
Next, cell damage was quantified in cells treated with cisplatin for 24 h using the lactate dehy-
drogenase (LDH) assay (Fig 1B). The result showed that 34.53% and 37.64% of cells were dam-
aged after treatment with 50 and 100 μM of cisplatin, respectively. Next, cell viability was
evaluated using propidium iodide (PI) and annexin V double-stain method (Fig 1C and 1D).
The results showed that 17.30% and 24.63% of cells were apoptotic and 11.77% and 20.13%
were necrotic at 50 μM and 100 μM cisplatin, respectively.
Similar results were observed when the fluorescence intensity of cells stained with the dyes
calcein AM and ethidium homodimer (EthD-1) was measured (Fig 1E). Calcein AM is incor-
porated into live cells where it produces green fluorescence, whereas EthD-1 binds to the DNA
of dead cells and produces red fluorescence [27]. From the fluorescence intensity, it was appar-
ent that the red fluorescence intensity increased proportionally to the cisplatin concentration.
Using fluorescence-activated cell sorting (FACS), quantitative data were obtained for the
increase in EthD-1 fluorescence intensity (Fig 1F) that corresponded to a 2.1- and 2.8-fold
increase at 50 μM and 100 μM of cisplatin, respectively, compared to that of control cells.
These results demonstrated that cisplatin causes cell death in HK-2 cells. Furthermore, con-
sidering these observations, 50 μM cisplatin (half-maximal inhibitory concentration) was used
in subsequent experiments.
Cellular gene ontology analysis showed significant expression profiles
and functional interactions
To examine transcriptome perturbations, mRNA levels were determined using the Affymetrix
GeneAtlas system and U219 array. Data were analyzed using the Affymetrix Expression
Console software and 2-fold transcriptional changes were considered significant at p< 0.01.
Cellular protein expression was analyzed using the liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) method. The number of identified spectra assigned to each peptide for
each LC-MS/MS run was counted. Peptides with an absolute value of the relative spectral
count (RSC) larger than the cutoff value (99
th percentile of RSC values obtained from 1000
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random permutation experiments; see Materials and Methods section) were regarded as differ-
entially expressed peptides (DEPs). As a result, 487 proteins with at least one DEP from 6 h/0 h
or 24 h/0 h comparisons were selected as DEPs. Therefore, gene ontology functions for those
5,692 differentially expressed genes (DEGs) and 487 DEPs were analyzed using the DAVID
software. DAVID provides online functional annotation tools for the analysis of sets of genes,
especially omics data, including microarray and high-throughput proteomic data [28,29],
which were visualized using Cytoscape [21,22].
The DAVID network derived from the effects of cisplatin in HK-2 cells provided an over-
view of the functional analysis (Fig 2). The complete functional network after identification of
all labeled nodes has been reported (S1 Fig). Each circular node corresponds to a gene set and
the circle size indicates the number of genes in it. The color of the inner and outer nodes repre-
sents the p-value of the enrichment analysis of transcriptomic data and proteomic data, respec-
tively. Each edge of a gene set represents gene overlap among gene sets and thickness of the
edges indicates similarity of genes among linked nodes [23].
Cisplatin causes changes in cell physiology, in particular, cell viability, cell cycle, DNA
repair, mitochondria, glycolysis, and transport function that were evident in both the transcrip-
tomic and proteomic analysis. We focused on functional anomalies in mitochondrial metabo-
lism and glycolysis and constructed a detailed functional map using STITCH and Cytoscape.
Using the STITCH database, protein-protein interactions in each homologue gene group
have been identified [30–32] and displayed through Cytoscape (S2 Fig). Each node indicates a
gene group, where the square node represents protein expression and the circular node repre-
sents mRNA expression. The node color represents fold changes in genes expression, i.e., red
indicates up-regulation and green indicates down-regulation. From these results, we identified
proteins and mRNAs with significant expression profiles and their functional interaction with
cisplatin in HK-2 cells.
Fig 1. Evaluation of cellular toxicity and viability in cisplatin-treated HK-2 cells.HK-2 cells were treated
with increasing concentrations of cisplatin (6.25–100 μM). (A) HK-2 cell proliferation was assessed byMTS
assay after 6, 12, and 24 h of cisplatin treatment. (B) Cells were treated with the indicated concentrations of
cisplatin for 24 h and cell death was measured. (C and D) HK-2 cells were washed twice with cold phosphate-
buffered saline (PBS), stained with Annexin V/propidium iodide (PI), and cell death was determined by flow
cytometry. (E and F) Cisplatin-induced cell viability and cytotoxicity assay using calcein AM and ethidium
homodimer (EthD-1) fluorescence staining with confocal microscopy (E) and flow cytometry (F). Magnification
of the images was ×40 and scale bars represent 75 μm. Themean ± S.D. (standard deviation) of three
independent experiments are presented; *p < 0.05, **p < 0.01, by paired t-test.
doi:10.1371/journal.pone.0135083.g001
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Cisplatin induced metabolic abnormalities in rat urine samples
To correlate the in vitro results to in vivo effects, rats were administered cisplatin. Urine was
collected at days 0, 1, and 3 post-injection and subjected to proton nuclear magnetic resonance
(1H-NMR) analysis. Fig 3A shows rat urine 1H-NMR spectra from day 1 (upper) and day 3
(lower) compared to control spectra. Only metabolites related to glycolysis and the TCA cycle
were analyzed (Fig 3B).
Interestingly, urine glucose levels were increased at day 3 after cisplatin administration,
whereas pyruvate levels were decreased compared to control. All TCA-related metabolites were
decreased in urine following cisplatin treatment (Fig 3C). The decrease in TCA metabolites
could be caused by inhibition of glycolysis or damage to mitochondria. Inhibition of glycolysis
leads to decreased production of pyruvate, a starting compound of TCA cycle. Moreover, the
TCA cycle occurs in the mitochondrial matrix; therefore, any damage to mitochondria would
also inhibit the TCA cycle.
Collectively, these results established that cisplatin blocked the glucose metabolism, which
is in agreement with the results of transcriptomic and proteomic analyses in cisplatin-treated
HK-2 cells.
Cisplatin treatment disrupted the mitochondrial membrane potential
ROS reduced cell viability, and cisplatin triggers ROS generation resulting in cell death [33–
35]. It was confirmed that ROS level increased in HK-2 cells to 22.54% and 58.93% after cis-
platin treatment for 12 and 24 h, respectively (S3A Fig), supporting earlier observations.
Cisplatin rapidly accumulates in mitochondria and induces oxidative stress that may dam-
age mitochondrial DNA [13,36–38]. Therefore, it was proposed that ROS are generated from
mitochondria due to accumulation of cisplatin. To confirm this, the location of ROS generation
was investigated in cisplatin-treated cells co-stained with Mito-tracker-Red CMX (Molecular
Fig 2. Functional analysis to visualize transcriptomic and proteomic data. Significantly altered genes in
HK-2 cells following cisplatin treatment as detected by microarray analysis (transcriptomic) and liquid
chromatography coupled with tandemmass spectrometry (LC-MS/MS) (proteomic). Functional analysis of
data was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID).
Results were visualized using the enrichment map plug-in for Cytoscape. Each circular node is a gene set
with a diameter proportional to the number of genes. The inner node color represents the p-value of the
enrichment analysis in the transcriptome, whereas the outer node color represents the p-value of the
enrichment analysis in the proteome. The edge width is proportional to the similarity of gene sets between
linked nodes. Details of the network can be examined using the scalable PDF in S1 Fig.
doi:10.1371/journal.pone.0135083.g002
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Probe, NY, USA) and the 20,70-dichlorofluorescein diacetate (DCFH-DA) fluorescence dye
(Fig 4A and S5A Fig). Co-staining revealed that the location of intracellular ROS generation
coincided with that of mitochondria. The overlap of Mito-tracker-Red-stained areas with
DCFH-DA-positive areas was>75% in cells after 24 h treatment. These co-localization results
demonstrated that cisplatin-induced mitochondrial ROS (mROS) generation is associated with
mitochondrial deterioration in HK-2 cells.
Next, the amount of mROS was determined using a two-photon (TP) probe for the ratio-
metric detection of mitochondrial H2O2. This TP probe was derived from 6-(benzo[d]thiazol-
2pryl)-2-(N,N-dimethylamino) naphthalene as the reporter, a boronate-based carbamate
leaving group as the H2O2 response site, and triphenylphosphonium salt as mitochondrial tar-
geting site. The reaction between the SHP-Mito probe and H2O2 would turn blue fluorescence
into yellow fluorescence [39]. Accordingly, the yellow/blue fluorescence ratio of mitochondrial
H2O2 increased up to 0.92 in cells treated with cisplatin for 24 h compared to untreated cells
(0.63) (Fig 4B and S5A Fig).
Morphologically, mitochondria from cisplatin-treated cells appeared disintegrated with
SHP-Mito probe when observed at digital high magnification (S4B Fig). Mitochondrial frag-
mentation has been shown to occur during cell injury and apoptosis and might be the result of
the activation of fission [40]. Next, the MMP was evaluated using the JC-1 fluorescence dye,
whose ratio of green-to-red fluorescence depends only on the membrane potential [41,42]. It
was observed that the fluorescence changed from red to green following cisplatin treatment in
a time-dependent manner (S3B Fig).
Furthermore, to confirm mitochondrial abnormalities, the expression level of genes related to
mitochondrial function—optic atrophy 1 (OPA1), pyruvate dehydrogenase kinase 1 (PDK1),
BCL2-interacting killer (BIK; apoptosis-inducing), ribonucleotide reductase M2 B (RRM2B), and
endonuclease-G (ENDOG)—were evaluated by quantitative reverse transcription polymerase
chain reaction (qRT-PCR) on the basis of transcriptomic data as shown in S2 Fig (Fig 4C).Opa1
is related to mitochondrial fission and fusion [43,44], whereas PDK1 is critical in conserving
mitochondrial functions [45]; both genes were down-regulated with time, which is in agreement
with previous results (Fig 4C). ENDOG, RRM2B, and BIK are markers of mitochondrial DNA
Fig 3. Metabolite profiling of cisplatin-treated rat urine samples. (A) Proton nuclear magnetic resonance
(1H-NMR) spectra of day 1 (upper) and day 3 (lower) after cisplatin injection compared with those of controls.
(B) Alterations of glycolysis- and tricarboxylic acid (TCA) cycle-related metabolites compared with control
samples. (C) Effect of cisplatin on the level of mitochondria-related metabolites in urine samples. The
mean ± S.D. of three independent experiments are presented; *p < 0.05, **p < 0.01, by paired t-test.
doi:10.1371/journal.pone.0135083.g003
Cisplatin Induces Metabolic Toxicity via mROS
PLOSONE | DOI:10.1371/journal.pone.0135083 August 6, 2015 10 / 21
damage and oxidative stress that are vital in a multitude of physiological aspects [46–50]; all
three genes were up-regulated in the presence of cisplatin.
Altogether, these results suggested that cisplatin causes mitochondrial dysfunction, frag-
mentation, and collapse of the membrane potential, via increased mROS generation.
Cisplatin-mediated inhibition of glycolysis led to increased cellular
glucose levels
Using LC-MS/MS, the expression level of enzymes involved in glycolysis, phosphofructokinase
platelet, phosphoglycerate kinase 1, aldolase A, phosphoglucomutase 1, triosephosphate isom-
erase 1 pseudogene 1, enolase 1, glyceraldehyde-3-phosphate dehydrogenase, and pyruvate
kinase muscle 2, were determined after 6 and 24 h of cisplatin treatment (Fig 4D) and found to
be down-regulated compared to the control. A reduction in the levels of these enzymes would
inhibit glycolysis.
Next, the expression levels of glycolysis pathway-related genes (HIF1α; hexokinase 2 [HK2];
protein kinase, AMP-activated, gamma 2 non-catalytic subunit [PRKAG2]; and aminocarboxymu-
conate semialdehyde decarboxylase [ACMSD]) were evaluated (Fig 4E), because transcriptomic
data indicated significant changes in their expression levels (S2 Fig).HIF1α induces glycolysis
enzymes [51],HK2 is the first enzyme of glycolysis [44], and PRKAG2modulates glycolysis
[52,53]. ACMSD acts as a regulatory link between glycolysis and nicotinamide adenine dinucleo-
tide synthesis [54]. All of these enzymes are necessary for the proper execution of glycolysis, but
Fig 4. Cisplatin induced ATP depletion via mitochondrial damage and inhibition of glycolysis. (A)
Intracellular localization of reactive oxygen species (ROS) by confocal microscopy. Visualization of
mitochondria by Mito-tracker Red CMX (red, middle) demonstrated co-localization with mitochondrial ROS
(mROS) as detected by the 20,70-dichlorofluorescein diacetate (DCFH-DA) (green, left) fluorescence dye.
Magnification of the images was ×100 and scale bars represent 30 μm. (B) Quantification of mROS by the
two-photon (TP) probe for the ratiometric detection of mitochondrial H2O2. The reaction between the
SHP-Mito probe and H2O2 resulted in a change in the fluorescence from blue to yellow. Pseudo-colored
green areas indicated mitochondria (blue fluorescence, left), and pseudo-colored red areas indicate
mitochondrial H2O2 (yellow fluorescence, middle). Magnification of the images was ×63 and scale bars
represent 26 μm. (C) mRNA expression levels of mitochondria-related genes (OPA1, PDK1, BIK, RRM2B,
and ENDOG) determined after cisplatin treatment by quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR). (D) Expression levels of glycolysis-related enzymes of cisplatin-treated cells using liquid
chromatography coupled with tandemmass spectrometry (LC-MS/MS) analysis. (E) mRNA expression
levels of glycolysis-related genes (HIF1a, HK2, ACMSD, and PRKAG2) determined after cisplatin treatment
using qRT-PCR. (F) Quantification of intracellular glucose levels after cisplatin treatment. (G) Intracellular
ATP levels were determined using LAS 1000 and a microplate reader. The mean ± S.D. of three independent
experiments are presented; *p < 0.05, **p < 0.01, by paired t test.
doi:10.1371/journal.pone.0135083.g004
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their expression levels decreased over time. This, in turn, resulted in abnormal glycolysis and
increased intracellular glucose levels (up to 75%) (Fig 4F), which also confirmed the results of the
omics data analysis.
Cisplatin lowered ATP levels via mitochondrial dysfunction and
glycolysis inhibition
Mitochondria are the vital organelles in cells to produce energy and have a central role in cell
proliferation and death signaling [40]. With the collapse of MMP (Δψm), mitochondrial deteri-
oration [55] or glycolysis disturbance [56], ATP depletion occurs.
To evaluate the ATP level in response to cisplatin treatment, the intracellular ATP level was
quantified using a luminescence assay (Fig 4G). Results showed that the ATP level decreased in
a time-dependent manner; particularly, in cells treated with cisplatin for 24 h, the ATP level
was reduced by 37.25% compared to untreated cells.
Cisplatin inhibited glycolysis via p53 activation, irrespective of
mitochondrial damage
Several studies have reported that cisplatin activates p53 [57,58]. Activated p53 inhibits glycol-
ysis via inhibition of HIF1α or induction of TP53-induced glycolysis and apoptosis regulator
[8–11].
Cisplatin induced total p53 and phosphorylated p53 (Fig 5A). When p53 was inhibited by
20 μM pifithrin-α (PFT-α) (Sigma-Aldrich) in cisplatin-treated cells and the expression levels
of glycolysis-related genes were determined by qRT-PCR (Fig 5B), it was found that the expres-
sion of genes suppressed by cisplatin induced p53 were restored. However, MMP and cellular
ATP levels were not affected (Fig 5D and 5E), while a decline in intracellular ROS levels was
observed by p53 inhibition (Fig 5F). Next, cell death was evaluated using PI and annexin V
double-staining (Fig 5G). Interestingly, in line to these observations, in PFT-α-treated cells, the
rate of cell death was significantly different for up to 24 h, and similar trend was observed after
48 h.
Finally, the intracellular glucose and lactate levels have been evaluated as p53 is the inhibitor
of glycolysis. When p53 was inhibited by PFT-α, intracellular glucose and lactate levels have
been significantly decreased, implying the restoration of glycolysis (S4A and S4B Fig).
Altered cellular events were restored by inhibition of ROS generation
As reported earlier, cisplatin-induced cytotoxicity is closely related to increased mROS genera-
tion [4,5]. Therefore, we investigated whether cisplatin-induced mROS generation was the
cause of the cellular damage phenomenon, including mitochondrial damage and exacerbation
of glycolysis.
N-acetylcysteine (NAC) is a powerful antioxidant, a precursor of glutathione [3] that can scav-
enge ROS to suppress its activity [2]. Therefore, cisplatin-induced ROS generation was sup-
pressed using NAC to elucidate the cisplatin-induced abnormalities that have been observed
previously in HK-2 cells. First, the effect of NAC on cisplatin-induced ROS generation was
studied using the DCFH-DA dye (S6A Fig). NAC significantly reduced cisplatin-dependent
intracellular ROS generation. Similarly, inhibition of ROS generation reduced expression and
phosphorylation of p53 (Fig 6A).
Next, the expression levels of glycolysis-related genes were analyzed in cisplatin and NAC
co-treated cells by qRT-PCR (Fig 6B). Compared to treatment with cisplatin alone, HIF1α,
HK2, ACMSD, and PRKAG2 were significantly up-regulated in cells co-treated with NAC.
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Moreover, the cisplatin-induced increase in the intracellular glucose level was also significantly
reduced by co-treatment with NAC (186.8% to 131.3%) (Fig 6C).
Furthermore, the effect of suppressed mROS generation on the mitochondrial status was
evaluated using SHP-Mito TP probe (Fig 6D). We found that the yellow/blue fluorescence sig-
nal from mitochondrial H2O2 decreased in NAC and cisplatin co-treated cells (0.79) compared
with cells treated with cisplatin alone (0.98) (S5C Fig). Mitochondrial fragmentation caused by
cisplatin was also ameliorated by NAC treatment (S5D Fig).
The expression level of the mitochondrial fission suppression gene OPA1, and PDK1
were significantly restored in the presence of NAC (Fig 6E). The apoptosis signal inducible
genes BIK, RRM2B, and ENDOG, which are present in mitochondria, were also significantly
down-regulated to their normal levels. These results demonstrated that NAC reversed cis-
platin-induced cellular damages.
Finally, intracellular ATP levels were investigated. By inhibiting mROS generation, mito-
chondrial dysfunction was improved and glycolysis was restored (Fig 6B–6E). This, in turn, led
to restoration of intracellular ATP levels, which were increased in cells co-treated with NAC
and cisplatin compared with cells treated with cisplatin alone (Fig 6F). The percentages of
annexin V- and PI-positive cells were 12.2% and 14.83%, respectively, in cells treated with cis-
platin alone; however, in NAC pre-treated samples, the respective values were 6.17% and 8.9%
(Fig 6G). Cell viability (S6B Fig) (42.27% to 70.36%) and morphology (S6C Fig) were signifi-
cantly improved and toxicity was reduced in cells co-treated with NAC.
Fig 5. Cisplatin inhibited glycolysis via p53 activation. (A) Western blot analysis indicated increased
levels of p53 and phospho-p53 after 6 and 24 h of cisplatin treatment. The gels have been run under the
same experimental conditions. (B) Expression of p53 in cells treated with pifithrin-α (PFT-α) (20 μM) was
analyzed by western blot. The gels have been run under the same experimental conditions. (C) mRNA
expression levels of glycolysis-related genes (HIF1a, HK2, ACMSD, and PRKAG2) determined in cisplatin-
treated and cisplatin/PFT-α (20 μM) co-treated cells by quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR). (D) Δψm depolarization monitored by FACS analysis with the JC-1 dye where a
fluorescence shift from red to green indicated the collapse of the mitochondrial membrane potential (MMP).
The number of cells with low MMPwas counted. (E) The intracellular ATP level was measured using LAS
1000 and a microplate reader. (F) Reduced levels of intracellular reactive oxygen species (ROS) were
observed in HK-2 cells with 20,70-dichlorofluorescein diacetate (DCFH-DA) following treatment with PFT-α
(20 μM). (G) Treatment with a p53 inhibitor prevented cisplatin-induced cell death at 48 h in HK-2 cells when
analyzed by Annexin V/propidium iodide (PI) staining. The percentage of apoptotic cells was determined by
flow cytometry. The mean ± S.D. of three independent experiments are presented; *p < 0.05, **p < 0.01, by
paired t-test.
doi:10.1371/journal.pone.0135083.g005
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Discussion
In recent years, several studies reported that cisplatin influenced different pathways, including
cell cycle arrest, apoptosis, proliferation, DNA repair, as well as the TCA cycle and glycolysis
[14,15,59]. However, it remained elusive how cisplatin affects metabolic pathways. Here, using
transcriptomic and proteomic data, the detailed mechanism has been unveiled, and a map
depicting the interactions among various genes has been drawn that clearly indicates the
down-regulation of different enzymes.
To analyze the cytotoxicity, different concentrations of cisplatin were applied to HK-2 cells,
which reduced cell viability and increased cell death in a dose-dependent manner (Fig 1). Next,
genome-wide analyses using microarray and LC-MS/MS revealed perturbations of numerous
pathways in cisplatin-treated cells (Fig 2). Many reports correlated cell cycle- and DNA repair-
related pathways to cisplatin toxicity; therefore, we analyzed metabolic enzymes in cisplatin-
induced cell death. Various glycolysis- and TCA cycle-related enzymes were down-regulated,
as shown in microarray and LC-MS/MS analyses (S2 Fig).
In vivo experiments involving rats confirmed the metabolic alterations, i.e., the level of vari-
ous metabolic intermediates were significantly decreased in cisplatin-treated rats (Fig 3B and
3C). This could be attributed to either damage to mitochondria where the TCA cycle occurs
[60] or disruption of glycolysis. Glucose and lactate levels were higher than normal; thus, it can
be postulated that glucose consumption is inhibited and glycolysis is deviated from pyruvate to
lactate, respectively (S4A and S4B Fig). Here, it was also considered that the glucose uptake
Fig 6. Restoration of altered cellular events by inhibition of mitochondrial reactive oxygen species
(mROS) generation. (A) Cisplatin-mediated expression and activation of p53 was evaluated and compared
with cisplatin andN-acetylcysteine (NAC) (10 μM) co-treated samples by western blot. The gels have been
run under the same experimental conditions. (B) mRNA expression levels of glycolysis-related genes (HIF1a,
HK2, ACMSD, and PRKAG2) were determined in cisplatin and NAC co-treated cells by quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR). (C) NAC reversed the cisplatin-induced increase in the
intracellular glucose concentration. (D) The amount of mROS was measured using a TP probe for the
ratiometric detection of mitochondrial H2O2. The reaction between the SHP-Mito probe and H2O2 resulted in
a change in the fluorescence from blue to yellow. Pseudo-colored green areas indicate mitochondria (blue
fluorescence, left) and pseudo-colored red areas indicate mitochondrial H2O2 (yellow fluorescence, middle).
NAC decreased mitochondrial H2O2 generation. Magnification of the images was ×63 and scale bars
represent 30 μm. (E) mRNA expression levels of mitochondria-related genes (OPA1, PDK1, BIK, RRM2B,
and ENDOG) were determined in cisplatin and NAC co-treated cells by qRT-PCR. (F) The intracellular ATP
level was restored following NAC treatment, as quantified by LAS 1000 and a microplate reader. (G) NAC
prevented cisplatin-induced cell death as evaluated by Annexin V/PI staining, and the ratio of apoptotic and
necrotic cells was determined using flow cytometry. The mean ± S.D. of three independent experiments are
presented; *p < 0.05, **p < 0.01, by paired t-test.
doi:10.1371/journal.pone.0135083.g006
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might be impaired. Nevertheless, microarray and MS data revealed that the glucose transporter
was expressed normally (data not shown); furthermore, glucose levels in the cytoplasm were
higher, ruling out impaired glucose transport.
Cisplatin down-regulated the genes involved in glycolysis (Fig 4D and 4E), which
resulted in glucose accumulation in HK-2 cells, causing ATP shortage (Fig 4F and 4G), and
was excreted via the urine (Fig 3B). Furthermore, mitochondrial damage by cisplatin was
evidenced through omics data (Figs 2 and 3) and mitochondrial staining experiments. Micro-
scopic analysis revealed enhanced ROS generation that was largely co-localized with mitochon-
dria, causing fragmentation, MMP disruption, and down-regulation of mitochondrial stability
markers (Fig 4 and S3B Fig). Hence, it was evident from these results that cisplatin induced
inhibition of glycolysis, TCA cycle dysfunction, and mitochondrial damage.
Several studies indicated the essential role of p53 in cisplatin-induced cytotoxicity [61,62].
In addition, it was noted that p53 was also up-regulated and phosphorylated upon cisplatin
treatment (Fig 5A), which resulted in the inhibition of the expression of glycolysis-related
genes; this effect was significantly reversed when p53 inhibitor (PFT-α) was applied (Fig 5C).
PFT-α treatment also reduced the intracellular glucose and lactate levels, implying the p53 role
in altered metabolic route (S4A and S4B Fig). However, MMP and ATP depletions were unaf-
fected by PFT-α treatment (Fig 5D and 5E). This might be correlated to dispensable role of p53
in aerobic respiration in cisplatin treatment, which is the principal source of ATP generation.
Also, PFT-α could not restore mitochondrial pathways, which strengthens this concept and
provides a plausible explanation of unaffected ATP level. Moreover, the results indicated that
p53 is downstream of mROS, because PFT-α application, only reversed the p53-dependent
pathways, whereas other pathways remained unaffected.
A previous study showed that, soon after its administration, cisplatin accumulated in mito-
chondria where it stimulated mROS generation that caused mitochondrial damage [63] and
induced other cytotoxic effects [4,5]. To confirm this, NAC was applied [64,65], which scav-
enged mROS and significantly improved the expression levels of mitochondrial markers in
treated cells, reduced fragmentation of mitochondria, significantly restored ATP levels, and
reduced cell death. Furthermore, the p53-induced decrease in the expression of glycolysis-
related genes and intracellular glucose levels were also recovered by treatment with NAC.
These observations indicated that mROS generation is an essential mediator of mitochondrial
and metabolic dysfunctions induced by cisplatin, which is in line to previous studies where the
quenching of mROS or the use of antioxidants leads to the amelioration of cisplatin induced
nephrotoxicity [63,66].
Intriguingly, there might a link between mROS and p53, because mROS induced p53
expression when cells were treated with cisplatin (Fig 6A). In fact, when a p53 inhibitor was
applied, low levels of mROS were generated (Fig 5F), suggesting a positive-feedback relation
between mROS and p53. Interestingly, a cell must undergo apoptosis when it becomes abnor-
mal rendered a positive feedback relation between mROS and p53 possible. In our study, cell
death was significantly reversed by inhibiting p53 for 24 h and for 48 h time points.
The mitochondrial inner membrane is vital for ATP generation via the electron-transport
chain (ETC). When cells were treated with cisplatin, the membrane potential decreased (S3B
Fig), which led to the collapse of energy generation and ATP depletion, sensitizing cells to apo-
ptosis. Moreover, it is unlikely to rule out the possibility of cytochrome C-mediated cell death;
hence, MMP and apoptosis are interlinked.
In cells, the main energy is provided in the form of ATP, which is primarily produced by
TCA/ETC, and in small quantities, by glycolysis. The ATP level has a central role in cell prolif-
eration and death signaling [40,55,56]. Cisplatin treatment disrupts central catabolic pathways;
consequently, intracellular ATP levels decreased that when this condition continues for a
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longer period, leading to cell death (Fig 4G). Moreover, fatty acid and protein metabolisms
were not studied because of their association to the glucose metabolism, therefore, impaired
glucose metabolism would certainly affect these pathways.
Cisplatin induced DNA damage is well appreciated in scientific community that triggers
p53 activation, which either rescues cells or leads to apoptosis. Alongside this perspective,
another view is that ROS is produced endogenously or in response to treatment, that also trig-
gers p53 [67], but the link describing cisplatin treatment and its metabolic disruption was not
established. In addition, the interaction of p53 and the ROS originated from mitochondria is
crucial to mediate the various cellular effects. ROS is a stress signal that also triggers p53, while
the p53 orchestrates the cell cycle and cell death, and metabolic pathways [68–71]. This coordi-
nated interplay of cellular and mitochondrial ROS and p53 can tweak the cellular behavior
towards various stress conditions as having been reported by previous studies [69,72]. More-
over, these results demonstrated that mROS is involved in stress-induced signaling upstream
of p53 activation, implying mROS role as the second messenger between mitochondrial ETC
and stress induced p53 activation.
Recent reports signified that cisplatin accumulated in mitochondria immediately after
administration [13,63], so we hypothesized that it may influence metabolism and mROS. We
found that up to 70% of the total ROS is generated by mitochondria in response to cisplatin
(Fig 4), therefore, we focused on the mitochondrial related abnormalities. The antioxidant,
NAC, can quench intracellular ROS that would suppress ROS-induced p53 activation (Fig 6),
which is in line with previous reports [3,73]. Moreover, mitochondria host the metabolism that
has been severely disrupted, so the effect of mROS on mitochondrial metabolism may provide
a useful link to treat cisplatin related abnormalities. In the present study, we focused on a less
appreciated prospect of cisplatin induced cell death that, despite DNA disruption, it also alters
metabolism that is being orchestrated by mROS.
Fig 7. Overview of the pathway xfor cisplatin-inducedmetabolic dysfunction in HK-2 cells.Cisplatin
induced mitochondrial dysfunction through mitochondrial reactive oxygen species (mROS) that also
interfered with the tricarboxylic acid (TCA) cycle and mitochondrial stability by inhibiting the expression of
enzymes and proteins essential for energy-producing pathways and the viability of mitochondria,
respectively. Furthermore, the collapse of the mitochondrial membrane potential (MMP) due to mROS led to
blockade of the electron-transport chain (ETC). On the other hand, mROS increased the transcription and
activation of the tumor suppressor protein p53, which suppressed glycolysis and, ultimately, reduced the
pyruvate level. Activated p53 also stimulated the generation of mROS, which had a synergistic effect on the
functions of both, p53 and mROS. Reduction of pyruvate decreased TCA cycle functionality, which was
already impaired by mROS. Therefore, cellular energy needs would not be met. Altogether, these changes
result in the activation of apoptotic and necrotic pathways.
doi:10.1371/journal.pone.0135083.g007
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Considering the results presented here, we proposed a model for the cellular responses to
the metabolic toxicity of cisplatin (Fig 7). Cisplatin accumulates in mitochondria and causes
over-production of mROS, which results in mitochondrial deterioration, impaired TCA cycle,
and disrupted MMP, resulting in ETC collapse. In parallel, generated mROS induces up-regu-
lation of p53 that inhibits glycolysis, leading to the accumulation of glucose and depletion of
pyruvate. The energy derived from glycolysis and mitochondrial metabolism ceases, resulting
in ATP depletion. Finally, continuous ATP depletion leads to cell cycle arrest and cell death.
In conclusion, this study proposed a viable framework for cisplatin-induced metabolic dys-
function and provided a novel explanation to correlate mROS and metabolic dysfunction. It
also provided the basis for a systems toxicology approach to explain mechanisms underlying
toxicity effects of other drugs.
Supporting Information
S1 Fig. Labeled gene ontology analysis enrichment map. Functional analysis of transcrip-
tomic and proteomic data was performed using Database for Annotation, Visualization, and
Integrated Discovery (DAVID). Results were analyzed using the enrichment map plug-in for
Cytoscape. A detailed functional network was drawn according to the identification of all
labeled nodes. Fig 2 can be visualized in detail using this network.
(PDF)
S2 Fig. Reconstruction of the gene and protein interaction network based on transcrip-
tomic and proteomic analyses. After isolating metabolism-related pathways, including tricar-
boxylic acid (TCA) cycle/mitochondrial metabolism and glycolysis from Fig 2, a detailed map
was created using STITCH and Cytoscape. Each square node indicates protein expression and
each circular node indicates mRNA expression. The color of the node represents the respective
fold change in the expression; red color represents up-regulation and green color represents
down-regulation.
(TIF)
S3 Fig. Effects of cisplatin in HK-2 cells. (A) Reactive oxygen species (ROS) production in
HK-2 cells was determined after 6 and 24 h of cisplatin treatment. This was performed using
the oxidant-sensitive probe 2ʹ,7ʹ-dichlorofluorescein diacetate (DCFH-DA). (B) Δψm depolari-
zation monitored by flow cytometry with the JC-1 mitochondrial potential marker. The shift in
JC-1 fluorescence from red to green indicates the collapse of the mitochondrial membrane
potential (MMP). The percentage of cells with low MMP was determined.
(TIF)
S4 Fig. Cisplatin induced increase in lactate and glucose concentrations that have been res-
cued by p53 inhibitor. (A) Glucose production in cells treated with cisplatin and 20 μM PFT-
α for 24 h. Cisplatin increased the glucose concentration significantly in the cells. PFT-α has
reversed the accumulation of glucose by cisplatin. (B) Lactate concentration in response to cis-
platin in the presence/absence of 20 μM PFT-α for 24 h.
(TIF)
S5 Fig. Ratio of fluorescence SHP-Mito dye density. (A) The fluorescence intensity of the
SHP-Mito probe was measured using the imageJ program. A yellow/blue fluorescence intensity
ratio of 0.63 was calculated for untreated cells; however, the yellow/blue ratio increased to 0.92
due to increased reactive oxygen species (ROS) generation in cells treated with cisplatin for
24 h. (B) Two-photon fluorescence microscopy analysis of the morphology of mitochondria
stained with the SHP-Mito probe at digital high magnification. Fragmentation of mitochondria
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was noted in the group treated with cisplatin for 24 h (right) compared with the untreated
group (left). Scale bar represents 15 μm. (C) The fluorescence intensity of the SHP-Mito probe
was measured using the imageJ program. A yellow/blue fluorescence intensity ratio of 0.98 was
calculated for cells treated only with cisplatin; however, the fluorescence ratio of N-acetylcys-
teine (NAC) (10 μM) and cisplatin co-treated cells decreased from 0.98 to 0.79 because mito-
chondrial ROS were scavenged. (D) Mitochondrial fragmentation caused by cisplatin was also
reduced by NAC (10 μM) treatment when cells were observed at digital high magnification.
Scale bars represent 20 μm.
(TIF)
S6 Fig. Restoration of altered cell morphology and proliferation by N-acetylcysteine
(NAC). (A) The effect of NAC (10 μM) on cisplatin-induced reactive oxygen species (ROS)
production was determined with the 2ʹ;,7ʹ-dichlorofluorescein diacetate (DCFH-DA) dye using
flow cytometry. NAC treatment reduced the cisplatin-induced ROS generation by 1.5- to
1.1-fold compared to the untreated control. (B) HK-2 cell proliferation was assessed by the
MTS assay. (C) The morphological features of HK-2 cells were assessed by phase contrast
microcopy (×200). Cell viability (B) and morphology (C) results also indicated that treatment
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